Current Challenges and Drug Delivery Updates in Vulvovaginal Candidiasis Treatment: A Comprehensive Review

To provide a comprehensive summary of a decade (2014-2025) of high-quality research from Q1-Q3 journals on formulation development and improved drug-delivery methods for vulvovaginal candidiasis, addressing the limits of conventional antifungal therapy. A detailed narrative review was carried out using PubMed, Scopus, Springer, Wiley, Frontiers, ClinicalTrials.gov, and Google Scholar. To maintain scientific rigor, only the most relevant Q1-Q3 indexed publications were included. Studies published in the last eleven years have been evaluated for their relevance to vaginal drug delivery systems and anti-fungal formulations. Data were systematically retrieved and described in text and tables, with 203 formulation techniques given, including nanoparticles, vesicular carriers, mucoadhesive systems, thermosensitive gels, electrospun nanofibers, microneedles, and three-dimensional printed dosage forms. The key outcomes examined were vaginal retention, drug release behavior, mucosal penetration, antibiofilm activity, and antifungal efficacy. In comparison to conventional formulations, advanced drug-delivery systems displayed longer vaginal residence time, sustained drug release, and improved tissue penetration. Nanoparticle-based and mucoadhesive systems demonstrated increased antifungal effectiveness against both microbial and biofilm-associated Candida species, with absolute fungal clearance improvements ranging from 25 to 45% in preclinical applications. This review combines eleven years of formulation research, minimizing the need for readers to sift over fragmented literature. Major limitations included study design variability and a lack of long-term clinical data. This 11-year synthesis identifies improved drug-delivery technologies as promising patient-centered solutions for overcoming resistance, recurrence, and poor drug retention in VVC treatment. These drug delivery systems constitute an important step toward next-generation antifungal therapy and better clinical outcomes.